MustGrow's Canola Field Trials Demonstrate Clubroot Disease Suppression; Improved Canola Yield with Healthier Root Systems
MustGrow's mustard-derived organic biocontrol technology TerraMGTM focuses on soil-borne disease and pest suppression, which has been shown to improve soil conditions, crop yields, and healthier root systems; Clubroot is a soil-borne parasitic disease with devastating effects on canola production across the Canadian Prairies with no effective products currently registered for Clubroot suppression; Fi
Agriculture, Biotechnology, Cannabis, Cannabis Breeder
2026-02-03 10:37 AM EST | MustGrow Biologics Corp.
Hemostemix Appoints Renowned Vascular Surgeon and Principal Investigator, Dr. York Hsiang, as Business Consultant to Advance First Nations-Led Healthcare Partnerships
Calgary, Alberta--(Newsfile Corp. - February 3, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous stem cell company treating those who suffer in pain from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, dilated cardiomyopathy, and vascular dementia, in Florida, Canada, The Bahamas, is pleased to announce the appointment of Dr. York Hsiang as a Business Consultant. "Since 2006, the first question I have
Biotechnology, Pharmaceuticals, Health
2026-02-03 8:55 AM EST | Hemostemix Inc.
Case Reports in Regrowth Announces Publication of Muhammad Qasim Observational Case Report and Invites Medical Review
New York, New York--(Newsfile Corp. - February 3, 2026) - Case Reports in Regrowth today announced the publication of an observational case report documenting late-onset hair regrowth and related physical observations in a 49-year-old male subject, Muhammad Qasim. The published case report presents a structured, non-clinical record compiled over an extended observation period. The documentation includes longitudinal v
2026-02-03 4:43 AM EST | Case Reports in Regrowth
Sharp Therapeutics Announces Private Placement of up to US$3.0 Million in Unsecured Convertible Notes
Pennsylvania and Toronto, Ontario--(Newsfile Corp. - February 2, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce the terms of a proposed non-brokered private placement for an aggregate principal amount of up to US$3.0 million of unsecured convertible notes of the Company (collectively, the "Notes"), in the principal amount of US$1,000 per Note (the "Note Offering"). The Company anticipates t
2026-02-02 12:10 PM EST | Sharp Therapeutics Corp.
PharmaTher Launches Strategic Initiative to Pursue Health Canada Approval for Generic Semaglutide in Canada, Building on FDA-Approved Ketamine Success
Toronto, Ontario--(Newsfile Corp. - February 2, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (the "Company" or "PharmaTher"), a specialty pharmaceutical company, today announced a new strategic initiative to pursue Health Canada approval for generic semaglutide in Canada and, subject to regulatory approval, its commercialization. Semaglutide is the active ingredient in Ozempic® and Wegovy®. The initiative builds on PharmaTher's demonstrated regulatory and partnering e
Biotechnology, Pharmaceuticals
2026-02-02 9:27 AM EST | PharmaTher Holdings Ltd.
Theralase(R) Completes Enrollment in Bladder Cancer Clinical Study
Toronto, Ontario--(Newsfile Corp. - February 2, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has successfully co
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-02-02 7:00 AM EST | Theralase Technologies Inc.
Aires Enters Collaboration Agreement with Leading Wellness Expert Gary Brecka's Brand, The Ultimate Human
Toronto, Ontario--(Newsfile Corp. - February 2, 2026) - American Aires Inc. (CSE: WIFI) (OTCQB: AAIRF) ("Aires" or the "Company"), a pioneer in advanced technology designed to transform electromagnetic field (EMF) environments to support health and well-being, entered a Collaboration Agreement (the "Agreement") with the Ultimate Human, LLC, the legal entity behind influencer Gary Brecka's wellness brand, The Ultimate
2026-02-02 6:00 AM EST | American Aires Inc.
OS Therapies Initiates US FDA BLA Filing for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
Request for FDA Rolling Review submitted to FDA on January 30, 2026 Non-Clinical and CMC BLA modules submitted to FDA At FDA's request, Type D Meeting expected in March 2026 to review Comparative Oncology biomarker data from patients treated in OST-HER2 Phase 2b human clinical trial and OST-HER2 trial in spontaneous osteosarcoma in canines Final BLA clinical module expected to be submitted to FDA by end of March 2026 after Type D Mee
2026-02-02 6:00 AM EST | OS Therapies
TempraMed Enters Strategic Media Partnership with Dr. Phil's Envoy Media, Validating Product Portfolio and Accelerating Market Adoption Across the United States
Vancouver, British Columbia--(Newsfile Corp. - February 2, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is excited to announce that it has entered into a strategic media partnership with Dr. Phil and Envoy Media, providing access to an audience of over 19 million monthly viewers which marks a significant step in acc
Technology, Biotechnology, Pharmaceuticals, Health
2026-02-02 3:00 AM EST | TempraMed Technologies Ltd
Telo Genomics Announces Appointment of John Price as Chief Financial Officer
Toronto, Ontario--(Newsfile Corp. - January 29, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, is pleased to announce that John Price has been appointed as Chief Financial Officer, effective immediately. Mr. Price was appointed as Chief Financial Officer effective January 30, 2026. Mr. Price has
2026-01-29 8:00 AM EST | Telo Genomics Corp.
Nextleaf Reports Fiscal Year 2025 Financial Performance
Vancouver, British Columbia--(Newsfile Corp. - January 28, 2026) - Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) ("Nextleaf", "OILS", or the "Company"), a multi-patented life science company and Canadian cannabis processor, is pleased to report its financial results for the Fiscal Year (FY) 2025. For the twelve months ended September 30, 2025, the Company delivered a transformative performance, including a dramatic reduction in net loss, increased gross profit, a
Biotechnology, Pharmaceuticals, Cannabis, Cannabis Extractor
2026-01-28 4:30 PM EST | Nextleaf Solutions Ltd.
Defence Therapeutics Expands Collaboration with Canadian Nuclear Laboratories to Accelerate Its Proprietary Radiopharmaceutical Pipeline
Montreal, Quebec--(Newsfile Corp. - January 28, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, today announced the strengthening of its long-standing collaboration with Canadian Nuclear Laboratories ("CNL") as part of its strategic effort to accelerate and expand its proprietary radiopharmaceutical program. Defence has been collaborating with CNL on th
Biotechnology, Pharmaceuticals, Health
2026-01-28 8:40 AM EST | Defence Therapeutics Inc.
Izotropic Provides Corporate Update & Announces Non-Brokered Private Placement
British Columbia and Sacramento, California--(Newsfile Corp. - January 28, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, provides a corporate update and announces the intention to complete a small non-brokered private placement fina
2026-01-28 8:00 AM EST | Izotropic Corporation
Scryb Reports Fiscal 2025 Results; Strengthened Balance Sheet and Significant Cybeats Exposure
Toronto, Ontario--(Newsfile Corp. - January 28, 2026) - Scryb Inc. (CSE: SCYB) ("Scryb'' or the "Company") announces that it has filed its audited consolidated financial statements and Management's Discussion and Analysis for the fiscal year ended September 30, 2025 ("FY2025"). The filings are available on SEDAR+. Fiscal 2025 marked a transformative year for Scryb, highlighted by a materially strengthened balance sheet, significantly reduced operating costs, and a
Biotechnology, Healthcare and Hospitals, Health
2026-01-28 7:03 AM EST | Scryb Inc.
Neural's Portfolio Company Hanf.com Announces Sales Start of Ritual Herbs Nicotine and Tobacco Free Products
Toronto, Ontario--(Newsfile Corp. - January 27, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for mental health conditions related to substance use disorders, together with its portfolio company CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one of Germany's leading CB
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-01-27 10:00 AM EST | Neural Therapeutics Inc.
Retinal Disease Expert Dr. Taiji Sakamoto Joins Kiora Pharmaceuticals' Scientific Advisory Board
Encinitas, California--(Newsfile Corp. - January 27, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) has appointed leading retina specialist, Dr. Taiji Sakamoto, an expert in the treatment of retinal disease, to its Scientific Advisory Board. As an advisor, Dr. Sakamoto, currently the Chair of Ophthalmology at Kagoshima University, will contribute clinical and scientific insights to Kiora as it develops new therapeutics to address retinal diseases with high unmet needs. "As we deep
Biotechnology, Pharmaceuticals
2026-01-27 7:00 AM EST | Kiora Pharmaceuticals, Inc.
Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference
King of Prussia, Pennsylvania--(Newsfile Corp. - January 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026 at the Borgata Hotel in Atlantic City, NJ. Robert Bitterman, CEO and Chairman of th
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-01-26 8:15 AM EST | Phio Pharmaceuticals Corp.
Optimi Health Completes First 2026 Production of MDMA and Psilocybin Capsules
Vancouver, British Columbia--(Newsfile Corp. - January 26, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical psychedelic drug products, today reported that it has completed a production cycle for its MDMA and psilocybin capsules intended for supply into Australia under the Authorised Prescriber Scheme. The completed batch consists of 1,000 MDMA capsules in a 60 mg dosage form and 1,000 n
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-01-26 7:00 AM EST | Optimi Health Corp.
TempraMed Launches New Product "VIVI Med(TM)," Unlocking New Growth Opportunities in High-Value Biologics and Injectable Medications
Highlights Uses same fully patented, thermal-protection technology across product portfolio with four products in market that keep room temperature medications at optimal temperature Designed for medications beyond standard insulin pens, including vials, biologics, GLP-1 therapies, alternative epinephrine auto-injectors, and temperature- and light-sensitive glucose test strips Expanded portfolio to pursue larger
Technology, Biotechnology, Pharmaceuticals, Health
2026-01-23 4:05 PM EST | TempraMed Technologies Ltd
Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million
Toronto, Ontario--(Newsfile Corp. - January 23, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has closed its previously announced private placement of units (the "Units") of the Company (the "Offering"), including the full exercise of the over-allotment option. Canac
Biotechnology, Cannabis, Health, Cannabis Manufacturer
2026-01-23 9:16 AM EST | Cardiol Therapeutics Inc.